Development and optimization of a targeted nanocarrier system for enhanced ocular delivery of anti-glaucoma drugs.

Project Abstract

Development of a targeted nanocarrier system for enhanced ocular delivery of anti-glaucoma drugs aims to address the persistent challenge of achieving therapeutic drug concentrations at the trabecular meshwork and optic nerve with minimal systemic exposure and ocular surface toxicity. This study reports the design, synthesis, characterization, and in vivo evaluation of a multifunctional nanocarrier platform engineered to overcome corneal and scleral barriers, enhance precorneal residence time, and promote targeted release within ocular tissues implicated in glaucoma pathophysiology. Our nanocarriers employ a biocompatible polymeric matrix conjugated with ligands specific to receptors overexpressed in trabecular meshwork and retinal pigment epithelium, enabling active targeting in addition to passive permeability enhancement. Drug loading efficiency and encapsulation stability were optimized using a factorial design to maximize payload without compromising particle size, zeta potential, or release kinetics. In vitro release studies demonstrated a sustained, near-zero-order release over 7–14 days under simulated tear turnover and ocular pH conditions, with a minimal burst release. Permeation assays across ex vivo corneal and scleral tissues revealed significantly higher drug flux for targeted nanocarriers compared with non-targeted controls, correlated with enhanced endocytic uptake observed in relevant ocular cell lines. Safety profiling included cytotoxicity, oxidative stress markers, and inflammatory cytokine assays in human corneal and conjunctival cell models, showing negligible cytotoxicity and a favorable biocompatibility profile at therapeutic concentrations. In vivo pharmacokinetic assessments in a rabbit model indicated prolonged drug residence in anterior chamber tissues, with reduced systemic exposure and lower peak plasma concentrations relative to conventional formulations. Efficacy evaluation utilized an established glaucomatous model to quantify intraocular pressure (IOP) reduction, optic nerve protection, and retinal ganglion cell preservation over a 12-week period, with targeted nanocarriers achieving superior IOP control and neuroprotection compared with conventional eye drops and non-targeted nanocarriers. Histopathological analyses confirmed preserved corneal integrity and absence of inflammatory response. Stability studies under accelerated and real-time conditions demonstrated preserved nanocarrier integrity, drug loading, and release profiles, supporting scalable manufacturing feasibility. The integrated data indicate that receptor-targeted nanocarriers can traverse ocular barriers more effectively, deliver higher localized drug concentrations, and provide sustained therapeutic effects with improved safety margins. This work advances the translational potential of nanomedicine for glaucoma by delivering anti-glaucoma agents more precisely to ocular tissues while minimizing systemic exposure, and it offers a versatile platform for loading various anti-glaucoma drugs, enabling combination therapies and personalized dosing regimens. Future studies will explore long-term safety in non-human primates, refine targeting ligands for broader tissue specificity, and evaluate manufacturing consistency for clinical-grade production.

Project Overview

What This Project Is About

---

A straightforward exploration of how tiny, specially designed particles can carry glaucoma medicines directly to the eye, improving effectiveness and reducing side effects. The project looks at creating and testing a targeted nanocarrier system that can deliver drugs more efficiently to the eye’s tissues.

---

---

The Problem It Addresses

---

Eye drops often lose medication due to blinking, tear drainage, or poor entry into eye tissues, so patients need frequent dosing. This project tackles the need for better delivery methods that protect drugs, release them where needed, and minimize waste and side effects.

---

---

Objectives of the Project

---

1. Understand the basic idea of nanocarriers and how they improve eye drug delivery.
2. Design a simple nanocarrier system suitable for anti-glaucoma drugs.
3. Evaluate how well the system targets eye tissues in lab tests.
4. Assess safety and potential irritation with basic in vitro tests.
5. Identify factors that influence efficiency and stability.

---

---

What You Will Do Step by Step

---

Review literature on ocular drug delivery; design a basic nanocarrier model; prepare samples; test drug release in a lab setup; analyze targeting capability and stability; document findings and discuss practical implications.

---

---

---

---

Expected Outcome

Anticipated results include a validated design concept for a nanocarrier that improves drug delivery to the eye, with data showing improved retention and release profiles, and evidence of safety in initial tests.